Updated Jul 16, 2026
Rosett Max has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.52M.
Max Rosett is the Chief Financial Officer of Immunome Inc., a biopharmaceutical company focused on developing antibody therapeutics. He has been involved in the financial management of the company, which specializes in oncology and infectious diseases.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-17 | IMNM | Immunome Inc. | S — Open-market sale | 60.0K | $18.23 | $1.09M |
| 2026-06-17 | IMNM | Immunome Inc. | M — Option exercise | 60.0K | $1.05 | $63K |
| 2026-04-03 | IMNM | Immunome Inc. | S — Open-market sale [10b5-1] | 1.3K | $22.48 | $30K |
| 2026-04-03 | IMNM | Immunome Inc. | S — Open-market sale [10b5-1] | 63.7K | $21.91 | $1.39M |
| 2026-04-03 | IMNM | Immunome Inc. | M — Option exercise [10b5-1] | 39.7K | $1.35 | $54K |
| 2026-04-03 | IMNM | Immunome Inc. | M — Option exercise [10b5-1] | 31.8K | $1.05 | $33K |
Max Rosett is the Chief Financial Officer of Immunome Inc., a biopharmaceutical company focused on developing antibody therapeutics. He has been involved in the financial management of the company, which specializes in oncology and infectious diseases.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($2.52M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Rosett Max profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.